An interventional study of OptiNIV and Visairo in COPD and Respiratory Acidosis, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Among the 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 11th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →4 of the 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+ · Healthy volunteers
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18–90
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 21 across the 10 interventional studies, 163 across the 2 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single-center, crossover study aims to investigate the effects of the new OptiNIV oronasal mask used during NIV in COPD patients with respiratory acidosis following an exacerbation. The goal is to evaluate whether the clinical benefits, in terms of reducing PaCO2 levels, are greater with the new mask compared to a traditional one (Visairo Mask).
Non-invasive ventilation (NIV) is considered the gold standard treatment, in combination with medical therapy, for patients with respiratory acidosis secondary to Chronic Obstructive Pulmonary Disease (COPD). The choice of interface is a key factor in the success of NIV. A new oronasal mask, designed to improve CO2 washout (OptiNIV, Fisher \& Paykel Healthcare, New Zealand), has recently been introduced to the market. Experimental data show that this interface, with a unique design separating airflow between the patient's mouth and nose, enhances gas flow at the end of expiration towards the oropharynx and subsequently out through the nostrils. This design facilitates the removal of CO2-rich air from the upper airways via dedicated ventilation ports located at the front of the mask, thereby optimizing CO2 clearance and dead space ventilation, which improves ventilatory efficiency.
This single-center, crossover study aims to investigate the effects of a new oronasal mask used during non-invasive ventilation (NIV) in COPD patients experiencing respiratory acidosis following an exacerbation. The objective is to assess whether the clinical benefits, specifically the reduction of PaCO₂ levels, are greater with the new mask compared to a traditional one. To minimize confounding factors affecting carbon dioxide washout, the new mask (OptiNIV, Fisher \& Paykel Healthcare, New Zealand) will be compared to a mask of similar size, internal volume, and technical features (Visairo, Fisher \& Paykel Healthcare, New Zealand), differing only in the presence of a separated airflow between the mouth and nose. This study holds significant clinical relevance, as no data are currently available on the use of the OptiNIV mask in patients with acute respiratory acidosis secondary to COPD exacerbation. The results could lead to optimized carbon dioxide clearance and improved ventilatory efficiency in managing patients with severe COPD exacerbations.
The study population consists of patients with respiratory acidosis secondary to COPD exacerbation who require non-invasive ventilation (NIV) and are admitted to the Respiratory and Critical Care Unit at the IRCCS AOU of Bologna, Policlinico S. Orsola. Patients meeting eligibility criteria will be randomly assigned (1:1) to two consecutive 60-minute NIV sessions using a traditional oronasal mask (Visairo) and an optimized mask (OptiNIV), following a crossover design. The sequence of mask use will be randomly assigned by the randomization list. NIV will be delivered with the same ventilator (ASTRAL 150 - ResMed Europe) using a single-limb circuit and pressure support mode, adjusting FiO₂ to maintain SpO₂ between 88-92%. Ventilator settings (IPAP, EPAP, triggers, rise time, Ti min, Ti max) will be set according to clinical practice but kept constant between sessions.
A 30-minute washout period with Venturi mask oxygen therapy will separate the two sessions, aiming to maintain SpO₂ between 88-92%. At the end of the washout, transcutaneous CO₂ (PtCO₂) will be measured; if this value is within ±2 mmHg of baseline, patient will proceed to the second session; otherwise, the washout will be extended up to 60 minutes. Including the washout, the total study duration per patient will not exceed 3 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo treatment with the OptiNIV Mask
Device: OptiNIV
Patients will undergo treatment with Visairo Mask
Device: Visairo
Patients assigned to the "OptiNIV" group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with an "optimized" mask (OptiNIV) and in the second session they will receive NIV with a traditional" oronasal mask (Visairo). The study will follow a crossover design, meaning each patient will undergo both sessions, In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours.
Patients assigned to the "Visairo" group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with a "traditional" oronasal mask (Visairo) and in the second session they will receive NIV with an "optimized" mask (OptiNIV). The study will follow a crossover design, meaning each patient will undergo both sessions. In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours.
Evaluation of the effects of the OptiNIV oronasal mask on partial pressure of carbon dioxide (PaCO₂) levels in patients with severe COPD exacerbation requiring treatment with non-invasive mechanical ventilation.
Measured through arterial blood gas analysis. Unit of measurement: mmHg
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in paO2
It will be measured through arterial blood gas analysis Unit of measuremet: mmHg
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in HCO3-
It will be measured through arterial blood gas analysis
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in pH
It will be measured through arterial blood gas analysis
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in PaO₂/FiO₂
It will be measured through arterial blood gas analysis
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in blood pressure
It will be measured using a sphygmomanometer Unit of measuremet: mmHg
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in the heart rate
It will be measured using a pulsoximeter Unit of measuremet: bpm
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in the respiratory pattern
It will be measured using the Minute Ventilation data and Respiratory Rate data obtained through a respiratory inductance plethysmography
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in the Ventilatory Ratio
It will be measured using the formula VR = (minute ventilation \[ml/min\] × PaCO₂) / (predicted weight \[kg\] × 100 × 37.5).
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in the end-tidal carbon dioxide (etCO₂)
It will be measured using a capnograph
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in the esophageal pressure swing
It will be measured via a nasogastric tube with an esophageal balloon.
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in the asynchrony index
It will be measured using the formula: AI = number of asynchronies / RR x 100 and will be measured by downloading the ventilator data at the end of each session
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in transcutaneous SpO₂ %
Will be measured via transcutaneous monitoring of SpO₂ that will be performed using a dedicated device that will record data for the entire duration of the study. Data at the end of each session will be compared with the data obtained at the beginning of the session. Unit of measure: %
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of changes in transcutaneous TcCO2
Will be measured via transcutaneous monitoring of TcCO2 that will be performed using a dedicated device that will record data for the entire duration of the study. Data at the end of each session will be compared with the data obtained at the beginning of the session. Unit of measure: mmHg
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of dyspnea
It will be measured using a visual analog scale (VAS) ranging from 0 to 100 where 0 represents minimum dyspnea and 100 represents maximum dyspnea
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of the comfort level experienced
It will be measured using a visual analog scale (VAS) with a score ranging from 0 to 10, where 0 represents maximum comfort and 10 represents maximum discomfort.
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Evaluation of NIV failure
NIV failure will be measured as the need for invasive mechanical ventilation (IMV)
Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).
Occurrance of adverse events
will be measured by recording any complications (skin irritation or ulcers, gastric distension, pneumothorax, hypotension, conjunctivitis, claustrophobia, aspiration) that occur during sessions with the two interfaces
Time frame: T1 ( + 1 hour) and at T3 (+ 3 hours).
Start is estimated for Aug 2025; primary completion for Oct 2026, 14 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 14 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
IRCCS Azienda Ospedaliero-Universitaria di Bologna →